Company intelligence / Profile preview
BioMimetix JV, LLC
Greenwood Village, Colorado, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
BioMimetix has developed BMX-001, a redox-active metalloporphyrin, which has demonstrated clinical efficacy and increased survival in high-grade glioma; positive Phase 2 data presented, Breakthrough Therapy designation from FDA, and preparing for Phase 3 pivotal trial in high-grade glioma. Early-stage trials in other solid tumors and dermatology indications such as atopic dermatitis.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Small moleculeRedox-active metalloporphyrin
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on BioMimetix JV, LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioMimetix JV, LLC.